Over the past 20 years, several coronaviruses have crossed the species barrier into humans, causing outbreaks of severe, and often fatal, respiratory illness. Since SARSCoV was first identified in animal markets, global viromics projects have discovered thousands of coronavirus sequences in diverse animals and geographic regions.
Every year, additional novel CoV sequences are discovered. However, there is a massive knowledge gap in the field as very little work is performed after the viral sequences are published. Therefore, it is unknown whether these novel viruses have the potential to emerge in human populations.
Current methods for studying novel β-CoVs are technically demanding. Viral isolation from field samples is rarely successful and reverse genetics recovery of recombinant virus is labor-intensive, and expensive as synthesis of a single genome can cost upwards of $15,000. These limitations are prohibitive to studying novel CoVs at the scale in which they are discovered.
Cell entry is an essential component of cross-species transmission, especially for the β-CoVs. All CoVs encode a surface glycoprotein, spike, which binds to the host-cell receptor and mediates viral entry 8 . For β-CoVs, a single region of the spike protein called the receptor binding domain (RBD) mediates the interaction with the host cell receptor.
After binding the receptor, a nearby host protease cleaves the spike, which releases the spike fusion peptide, facilitating virus entry [9] [10] [11] [12] . Known host receptors for β-CoVs include angiotensin converting enzyme 2 (ACE2) for SARS-CoV and dipeptidyl peptidase 4 (DPP4) for MERS-CoV 13, 14 .
Structural studies of coronaviruses have shown that the spike RBD is capable of folding independently from the rest of the spike protein and contains all of the structural information for host receptor binding 15 . Additionally, a previous study showed that replacing the RBD of the lineage B bat virus, Rp3, allowed the virus to enter cells expressing human ACE2 (hACE2) 16 . We therefore developed a method to functionally test the RBDs from novel lineage B β-CoVs in place of the SARS-CoV spike RBD ( figure   1 ). Synthesizing just the RBD of spike is much faster and cost-effective than conventional pseudotyping methods that rely on synthesis of the full ~4kb spike sequence for novel
CoVs: a process that can take weeks and is cost-prohibitive for large panels of spike sequences. The short turnaround time for our approach allowed us to test the receptor usage of all published, unique RBD sequences in lineage B, and also rapidly confirm the ACE2 receptor usage of the 2019-nCoV spike, which emerged in China in January 2020 as our study was ongoing.
We show that lineage B RBDs divide into functionally distinct clades and that several previously-unappreciated viruses exhibit compatibility with an unknown receptor on human cells. We also show that these clades are capable of recombining to impart human host-cell entry phenotypes, and that, beyond the RDB-receptor interaction, host protease processing is another species barrier encountered by lineage B β-CoVs during cell entry. were synthesized and cloned into pcDNA3.1+ (GenScript). All DNA constructs were verified by Sanger sequencing (ACGT Inc.).
Methods

Cells
Receptor transfection
BHK cells were seeded in black 96-well plates and transfected the next day with 100ng plasmid DNA encoding human ACE2, DPP4, APN or empty vector, using polyethyleneimine (Polysciences). All downstream experiments were performed 24 hours post-transfection.
Pseudotype production
Pseudotypes were produced as previously described 18 . 293T cells were seeded onto 6-well plates pre-coated with poly-L-lysine (Sigma) and transfected the next day with 1200ng empty plasmid and 400ng of plasmid encoding coronavirus spike or GFP as a no pseudotype control. Twenty-four hours later, transfected cells were infected with VSVΔG particles pseudotyped with VSV-g as previously described 19 . After one hour of incubating at 37°C, cells were washed three times and incubated in 2mL DMEM supplemented with 2% FBS, penicillin/streptomycin, and L-glutamine for 48 hours. Supernatants were collected, centrifuged at 500xG for 5 minutes, aliquoted and stored at -80. Approximately 18-20 hours post-infection, Bright-Glo luciferase reagent (Promega) was added to each well, 1:1, without removing culture media and luciferase was measured.
Luciferase-based cell entry assay
Relative entry was calculated by normalizing the relative light unit (RLU) for spike pseudotypes to the plate RLU average for the "no pseudotype control."
Western blot
Producer cells (spike-transfected 293T) were lysed in 1%SDS, 150mM NaCl, 50mM Tris-HCl, 5mM EDTA and clarified by centrifugation at 14000xG for 20 minutes.
Pseudotyped particles were concentrated from producer cell lysates that were overlaid a 10% OptiPrep cushion in PBS (Sigma) and centrifuged at 20,000× g for 2 hours at 4 °C.
Lysates and concentrated particles were analyzed for FLAG, GAPDH and/or VSV-m expression on 10% Bis-Tris PAGE gel (ThermoFisher).
Accession numbers
Accession numbers for all spike sequences used here can be found in figure s1b.
Results
ACE2 entry is lineage B clade 1-specific
The receptor binding domain ( 
Protease enhances clade 2 entry
After binding the host receptor, host-cell protease cleaves spike, releasing the fusion peptide and allowing for host cell entry 20 . Previous studies have shown that absence of the host protease or incompatibility between the host protease and viral spike can block viral entry [21] [22] [23] [24] . To circumvent host-cell protease incompatibility or absence, we treated our lineage B pseudotype panel and infected a wide variety of cell types from different host species (figure 2, supp. fig. 2 ). In the absence of exogenous protease, only . Surprisingly, exogenous protease enhanced entry of a subset of clade 2 spike chimeras in nonhuman primate, bat and human cells (figure 2). Importantly, VSV-g pseudotyped particles were able to produce luciferase signal in all cell lines tested in this study (supp. fig. 2c ).
Clade 2 entry is receptor-dependent
We next tested human variants of known β-CoV receptors for their ability to mediate cell entry of clade 2 and 3 spike chimeras. We also 
Clade determinants for ACE2 usage
Consensus sequences of the three lineage B clades showed several key differences between these groups. Only clade 1 RBDs contain all 14 residues that have been shown through crystallography, to interact with human ACE2 (figure 4a; s4). The majority of these residues are absent from clades 2 and 3, which contain additional deletions in surface exposed loops that cluster at the interface with ACE2 ( figure 4 a, b) .
We generated a series of clade consensus RBD variants to determine the minimum number of mutations needed to impart ACE2 function on clade 2 and 3 RBDs (figure 4c).
Introducing the two loop deletions from clade 1 in clade 2 results in a reduced spike expression, impaired pseudotype incorporation and loss of cell entry ( figure 4c, d ).
Restoring these loops in clade 2 and 3 from the loops found in clade 1 did not enhance entry with ACE2 (figure 4c; 2→1 and 3→1 version 1). Introducing all 14 ACE2 contact points in clade 2 or 3 also failed to restore ACE2 entry (figure 4c; 2→1 and 3→1 version 2). Only replacing all 14 contact points and the surrounding amino acids (also known as the receptor binding motif, RBM) lead to increased ACE2 entry with clade 2 and 3 RBDs (figure 4c; 2→1 version 3 = clade 2 residues 322-400 + clade 1 residues 400-501; 3→1 version 3 = clade 3 residues 322-385 + clade 1 residues 386-501). Taken together, these results show that the entire RBM from clade 1 is needed for ACE2 entry.
Full-spike and RBD chimeras are comparable
We next synthesized full-length clade 2 and 3 spikes to compare to our RBD chimeras. We selected the clade 2 spike, As6526, because it consistently gave strong entry signal in human cells following protease-treatment (figure 2b) as well as BM48-31, the only clade 3 spike in our panel. As we did for SARS-CoV spike, clade 2 and 3 spikes were codon optimized, FLAG-tagged and silent mutations were introduced to facilitate replacing their RBD with the consensus RBD from clade 1 (figure 5a). All chimeric constructs expressed similarly, with the exception for the SARS-BM48-31 RBD chimera, which exhibited reduced expression and incorporation (figure 5b). Protease treatment enhanced entry of both the As6526 clade 2 RBD chimera and full-length spike entry into Huh cells (figure 5c). Protease treatment had no effect on either the BM48-31 clade 3 chimera or full-length spike (figure 5c). Taken together, these findings show that SARSlineage B RBD chimeras reflect the entry phenotype of full-length lineage B spikes. 
Discussion
Despite significant advances in next generation sequencing technologies, which have facilitated the discovery of thousands of novel animal-derived viruses, tools for downstream functional assessment of these novel sequences are lacking. To gain traction on this ever-growing problem, we took a reductionist approach to coronavirus entry and developed a scalable, BSL2-compatible method for testing only the minimal region of the virus essential for interacting with the host receptor ( figure 1, figure s1a ).
Because most of these viruses have never been isolated, we resorted to synthetic biology and molecular engineering to reduce the burden of gene synthesis to just a small fragment. Thus, the cost and synthesis production time for testing several spikes for entry in our system is dramatically reduced (figure s1d). In theory, this approach to functional viromics should be applicable to a wide variety of virus-host proteins and interactions.
Coronavirus entry is a multi-step process involving multiple, distinct domains in spike that mediate virus attachment to the cell surface, receptor engagement, protease processing and membrane fusion 8 . While the RBD:receptor interaction is most studied in this process, recent studies have highlighted the major role host protease processing plays as a species barrier 22, [25] [26] [27] . Lineage C coronaviruses include MERS-CoV as well as distantly related viruses such as HKU4, HKU5 and PDF-2180 28, 29 . Studies have shown that HKU4 can bind human DPP4 but requires addition of exogenous trypsin to facilitate cell entry and that HKU5 and PDF-2180 spikes can enter human cells through an unidentified receptor with protease treatment 22, 26 . Analogous to these earlier studies of lineage C CoVs, we observed protease-enhanced entry of lineage B CoVs (figure 2, 3, 5). While it has been shown that host proteases cleave spike, allowing for downstream membrane fusion, other evidence suggests that protease may act on the receptor as well to activate it 30 . Addition of protease during the course of SARS-CoV infection facilitated entry in cells with low-expression of ACE2 that is normally insufficient to support virus entry 30 . Indeed, we saw evidence of residual trypsin activity on the cells after infection in our studies as the cell monolayer was loose compared to the untreated condition.
Similarly, Menachery et al. also observed cell rounding during their trypsin infections 26 .
Therefore, further studies are needed to assess where trypsin is enhancing entry of coronaviruses: at the level of spike, the receptor, or both.
In None of the spike pseudotypes efficiently entered Rhinolophus cells, which has been observed in previous studies using these cells 32, 33 ( figure 2c) . Surprisingly, AJi cells were selectively permissive for only clade 2 entry following protease treatment, which suggests that clade 2 RBDs interact with a receptor that is distinct from clade 1 (figure 2c).
Our results show that, despite all being classified as the same virus species, most lineage B β-CoVs do not use currently known coronavirus receptors ( figure 1e, 3a, b) .
Critically, we did not observe any pseudotype entry in the presence of protease and absence of receptor, suggesting that lineage B cell entry is still receptor-dependent following protease treatment (figure 3b). While our study was ongoing, a novel lineage B β-CoV was identified as the etiological agent behind an outbreak of pneumonia in Wuhan,
Hubei, China (2019-nCoV). The RBD for 2019-nCoV has residues and motifs found in all 3 clades but forms a distinct clade, so we tested it for receptor usage and observed entry only with human ACE2 but not other known coronavirus receptors (figure 3d).
Interestingly, within the backbone of SARS-CoV spike, cell entry of 2019-nCoV was similar to the other clade 1 spikes tested, including SARS-CoV. These finding suggests 2019-nCoV is capable of using human ACE2 as efficiently as SARS-CoV, which may help explain the human-to-human transmissibility of this virus. More studies are needed with the full spike sequence and, ideally, a viral isolate.
The receptor binding motif (RBM) is a small region in the C-terminal half of the RBD and contains all the residues that interface with the host receptor (figure 3a) 15 . The 14 contact points in the co-structure of the SARS-RBD bound to human ACE2 are largely absent from clade 2 and 3 RBDs, which also contain deletions compared to clade 1 RBMs (figure 4a, b, s4a). Simply mutating clade 2 and 3 to have the 14 contact points was insufficient to impart human ACE2 usage (figure 4c). This is likely because the noncontact residues in the RBM play a supportive and structural role for these contact points, and indeed, these non-contact residues are different between the clades (figure s4).
In contrast to changing individual amino acids, our chimeric RBD constructs show that clade 2 and 3 RBD containing the clade 1 RBM are compatible with human ACE2.
Coronaviruses frequently undergo recombination, gaining large swaths of genetic material at once 34, 35 . Taken together with our data, it is possible that recombination with a clade 1 virus will impart compatibility with human ACE2. Interestingly, the 2019-nCoV RBD forms a clade that is distinct from the other 3 clades (figure s1c). However, the 2019-nCoV RBD contains most of the contact points with human ACE2 that are found in clade 1 as well as some amino acid variations that are unique to clade 2 and 3 (figure s4b).
Taken together with our receptor assay results, it may be possible that 2019-nCoV arose from recombination between clade 1 and the other clades.
As we saw with the SARS-As6526 RBD (clade 2) spike chimera, full length As6526 spike entered cells following protease treatment, but BM48-31 (clade 3) spike did not ( figure 2, 5c ). These data show that the chimeric spikes generally reproduce the entry phenotypes of full-length spikes. Notably, the full length As6526 spike did not enter cells as efficiently as the SARS-As6526 chimera, suggesting that other human-cell adaptations are likely needed in As6526 spike.
The capacity to predict the zoonotic potential of newly detected viruses has been severely hindered by a lack of functional data for these novel animal virus sequences.
Here, we have developed a rapid and cost-effective platform to functionally test large groups of related viruses for zoonotic potential. We found that several other lineage B 
